Total N=170 CONUT <2 N=93 CONUT ≥2 N=77
p
Age (Years) 68.27±10.23 66.17±10.23 70.81±9.70 0.003
Male 105 (61.8%) 55 (59.1%) 50 (64.9%) 0.439
Follow-up period (Months) 50 (41-60.25) 52 (42.5-59) 48 (37-64.5) 0.306
Mortality 40 (23.5%) 13 (14%) 27 (35.1%) 0.001
New-onset stroke (Follow-up period) 4 (2.4%) 1 (1.1%) 3 (3.9%) 0.330*
MACE 44 (25.9%) 15 (16.1%) 29 (37.7%) 0.001
Hypertension 126 (74.1%) 67 (72%) 59 (76.6%) 0.497
Diabetes mellitus 63 (37.1%) 33 (35.5%) 30 (39%) 0.640
Dyslipidemia 130 (76.5%) 76 (81.7%) 54 (70.1%) 0.076
Active smoking 82 (48.2%) 48 (51.6%) 34 (44.2%) 0.333
CAD 104 (61.2%) 61 (65.6%) 43 (55.8%) 0.194
PAD 7 (4.1%) 4 (4.3%) 3 (3.9%) 0.652
Stroke 66 (38.8%) 31 (33.3%) 35 (45.5%) 0.106
Transient ischemic attack 73 (42.9%) 39 (41.9%) 34 (44.2%) 0.771
Amaurosis fugax 13 (7.6%) 8 (8.6%) 5 (6.5%) 0.607
Rhythm Sinus rhythm Atrium fibrillation 161 (94.7%) 9 (5.3%) 87 (93.5%) 6 (6.5%) 74 (96.1%) 3 (3.9%)
0.459
Stented vessel Right Carotid Artery
78 (45.9%)
49 (52.7%)
29 (37.7%)
0.050
Left Carotid Artery 102 (60%) 50 (53.8%) 52 (67.5%) 0.068
Left carotid stenosis 0-50% 50-69% 70-89% 90-100% 55 (32.4%) 5 (2.9%) 43 (25.3%) 67 (39.4%) 36 (38.7%) 2 (2.2%) 23 (24.7%) 32 (34.4%) 19 (24.7%) 3 (3.9%) 20 (26%) 35 (45.5%)
0.218*
Right carotid stenosis 0-50% 50-69% 70-89% 90-100% 89 (52.4%) 3 (1.8%) 42 (24.7%) 36 (21.2%) 42 (45.2.7%) 3 (3.2%) 29 (31.2%) 19 (20.4%) 47 (61%) 0 (0%) 13 (16.9%) 17 (22.1%)
0.040*
ASA/clopidogrel 170 (100%) 93 (100%) 77 (100%) **
ACEI/ARB 112 (65.9%) 61 (65.6%) 51 (66.2%) 0.930
Beta-blocker 118 (69.4%) 61 (65.6%) 57 (74%) 0.235
Statins 162 (95.3%) 89 (95.7%) 73 (94.8%) 0.784
Body mass index, kg/m2 25.22 (24.08-27.2) 25 (24.03-26.94) 25.40 (24.21-27.45) 0.398
Ejection fraction (%) 60 (60-60) 60 (55-60) 60(60-60) 0.231
SBP mmHg DBP mmHg 130 (120-137) 76.5 (70-80) 130(120-136) 76(70-80) 130(120-138) 78(70-80) 0.539 0.752
Prognostic nutritional index 46.35±6.59 50.12±4.57 41.81±5.76 <0.001
Neutrophil to lymphocyte ratio 2.53(1.93-3.46) 2.25(1.81-2.83) 2.96(2.25-4.9) <0.001